ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

IMMUNOTOXINS: An Update (1996)

Thrush, Gerald R. ; Lark, Laura R. ; Clinchy, Birgitta C. ; [et al.]

Palo Alto, Calif. : Annual Reviews

Annual Review of Immunology 14 (1996), S. 49-71

add to mindlist on the mindlist

Details

ISSN: 0732-0582

Source: Annual Reviews Electronic Back Volume Collection 1932-2001ff

Topics: Biology , Medicine

Notes: Abstract The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell. Newly developed MoAbs, toxins, and molecular biological technologies have enabled researchers to construct ITs that can effectively kill many different cell types. In fact, phase I/II clinical trials have given promising results. Although nonspecific toxicity and immunogenicity still limit the use of IT therapy, these agents hold enormous promise in an optimal setting to treat minimal disease.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1146/annurev.immunol.14.1.49

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice (2000)

Clinchy, Birgitta ; Gazdar, Adi ; Rabinovsky, Rosalia ; [et al.]

Springer

Breast cancer research and treatment 61 (2000), S. 217-228

add to mindlist on the mindlist

Details

ISSN: 1573-7217

Keywords: breast cancer ; in vivo tumor models ; Her-2/neu ; metastasis ; SCID mice ; soluble Her-2

Source: Springer Online Journal Archives 1860-2000

Topics: Medicine

Notes: Abstract HER-2/neu is overexpressed on a variety of human adenocarcinomas and overexpression has been associated with a poor prognosis. For this reason, HER-2 has become an attractive target for immunotherapy. To facilitate testing of anti-HER-2-monoclonal antibodies (MAbs) and immunotoxins (ITs), we have evaluated the in vivo growth and metastatic spread of three HER-2-overexpressing human breast cancer cell lines (BT474, MDA-MB-453 and HCC1954) and one ovarian cancer cell line (SKOV3.ip1) in pre-irradiated male SCID mice using subcutaneous (s.c.), intravenous (i.v.) and intraperitoneal (i.p.) routes of injection. All the cell lines tested grew as s.c. tumors and the growth of BT474 and MDA-MB-453 cells after s.c. injection was improved by co-inoculation with Matrigel. Metastases to the lungs were detectable by PCR or histopathology after s.c. injection of BT474 and to a much lesser extent after s.c. injection of HCC1954, MD-MB-453 and SKOV3.ip1cells. I.P. injection of HCC1954 and SKOV3.ip1 cells produced fatal ascites while i.v. injection of SKOV3.ip1, but not BT474 or MDA-MB-453 cells, resulted in infiltration of lungs and death within 9–11 weeks.